Trial Profile

Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin) in Patients With Advanced or Metastatic Triple-negative Breast Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Paclitaxel (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms ATRACTIB

13 Dec 2023 Status changed from recruiting to completed.
08 Dec 2023 According to a Medica Scientia Innovation Research Media Release, data from this study were presented at the 46th San Antonio Breast Cancer Symposium (SABCS).
08 Dec 2023 Results presented in a Medica Scientia Innovation Research Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com